Poly Medicure Limited has released its investor presentation for Q1 FY27, detailing significant financial performance and key business updates. The company reported consolidated revenue growth of 30.3% YoY and highlighted its strategic initiatives in product launches, R&D, and ESG commitments. The presentation also provides a detailed breakdown of standalone and consolidated financial performance for the quarter ending June 30, 2026.
Poly Medicure Unveils Q1 FY27 Financial Performance and Strategic Updates
Poly Medicure Limited has published its investor presentation for the first quarter of the financial year 2027 (Q1 FY27), concluding on June 30, 2026. The document provides a comprehensive overview of the company’s financial results, key business developments, product launches, and its commitment to Environmental, Social, and Governance (ESG) principles.
Financial Highlights
The company reported a strong 30.3% YoY growth in consolidated revenue for Q1 FY27, reaching ₹525.4 crore. Domestic revenue saw a growth of 16.2% YoY, while international revenue increased by 36.7% YoY. Standalone revenue grew by 12.3% YoY to ₹431.1 crore. Operating EBITDA for standalone results stood at 28.0%, exceeding the guided range of 25%-27%, and consolidated Operating EBITDA margin was 24.1%, within the guided range of 23-25%. The company maintains adequate liquidity, with ₹854.7 crore in cash and cash equivalents as of June 30, 2026.
Key Business Updates and Strategic Focus
Poly Medicure has made key appointments, including Mr. Indranil Mukherjee as CEO – India & APAC and Mr. Renato Rocha as CEO of Polymed Brazil. Cumulative stent deployments have surpassed ~13K units, with encouraging preclinical data for DEB-Ex-Vivo. The PACIFIER DES registry has enrolled over 840 patients, targeting full enrollment by the end of FY27. Furthermore, cumulative dialysis machine installations have grown to ~1,100 units.
Product Launches and R&D
In Q1 FY27, the company launched 6 new products across Infusion Therapy and Critical Care segments. The R&D team strength stands at 90+ professionals across India, Italy, and Netherlands, underscoring a commitment to innovation.
ESG Initiatives
Poly Medicure continues its focus on sustainability, achieving an ~18% reduction in scope 2 emissions through increased utilization of solar and renewable energy PPAs. Solar power generation has seen a 6x growth. The company is also progressing with its BRSR and Sustainability Report assessments.
Awards and Accolades
The company has been recognized for its contributions, recently receiving the “Custodian Award for Best CSR Initiative in Healthcare, Education and Social Welfare” by Medgate Today. Poly Medicure was also awarded “500 Most Valuable Companies List 2025” by Hurun India.
Source: BSE
